Section 2 trial of bezisterim for newly recognized Parkinson’s advances
The deliberate Section 2 SUNRISE-PD scientific trial of oral bezisterim as a first-line, stand-alone remedy for newly recognized Parkinson’s illness sufferers is scheduled to start out in early 2025. BioVie, the treatment’s